DAY ONE BIOPHARMACEUTICALS I's ticker is DAWN and the CUSIP is 23954D109. A total of 108 filers reported holding DAY ONE BIOPHARMACEUTICALS I in Q4 2022. The put-call ratio across all filers is 0.31 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,771,248 | +31.1% | 551,854 | +27.6% | 0.00% | 0.0% |
| Q2 2023 | $5,165,148 | +76.0% | 432,592 | +97.1% | 0.00% | 0.0% |
| Q1 2023 | $2,934,996 | -39.5% | 219,521 | -2.6% | 0.00% | 0.0% |
| Q4 2022 | $4,847,790 | +7.6% | 225,269 | +0.1% | 0.00% | 0.0% |
| Q3 2022 | $4,507,000 | +32.2% | 225,050 | +18.1% | 0.00% | 0.0% |
| Q2 2022 | $3,410,000 | +101.9% | 190,510 | +11.9% | 0.00% | – |
| Q1 2022 | $1,689,000 | -3.3% | 170,299 | +64.3% | 0.00% | – |
| Q4 2021 | $1,747,000 | -25.0% | 103,677 | +5.7% | 0.00% | – |
| Q3 2021 | $2,328,000 | +702.8% | 98,099 | +671.3% | 0.00% | – |
| Q2 2021 | $290,000 | – | 12,718 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Canaan Partners XI LLC | 2,548,403 | $54,841,633 | 43.06% |
| PATHWAY CAPITAL MANAGEMENT, LP | 995,686 | $21,427,163 | 38.24% |
| Atlas Venture Life Science Advisors, LLC | 7,568,317 | $162,870,182 | 19.62% |
| RA Capital Management | 7,040,622 | $151,514,185 | 3.07% |
| COMMODORE CAPITAL LP | 739,661 | $15,918 | 2.40% |
| GREAT POINT PARTNERS LLC | 544,451 | $11,716,586 | 2.30% |
| Nicholas Investment Partners, LP | 786,554 | $16,926,642 | 1.48% |
| Boxer Capital, LLC | 1,189,943 | $25,607,573 | 1.35% |
| Parkman Healthcare Partners LLC | 224,483 | $4,830,874 | 1.29% |
| Cheyne Capital Management (UK) LLP | 27,223 | $585,839 | 1.02% |